Search scope:
排序： Display mode:
Ting Liu, Faping Wang, Geng Wang, Hui Mao
Frontiers of Medicine 2018, Volume 12, Issue 3, Pages 340-349 doi: 10.1007/s11684-017-0565-0
Benralizumab is a monoclonal antibody that targets interleukin-5 receptor α to deplete bloodWe conducted a meta-analysis to evaluate the safety and efficacy of different doses of benralizumab inAll randomized controlled trials involving benralizumab treatment for patients with eosinophilic asthmaCompared with the placebo, benralizumab treatment demonstrated significant improvements in the forcedBenralizumab treatment was also not associated with increased adverse events.
Keywords： benralizumab anti-interleukin-5 monoclonal antibody eosinophilic asthma meta-analysis
Title Author Date Type Operation
京公网安备 11010502051620号
